PolyNovo to file with FDA to seek NovoSorb in US
04 February, 2013 by Tim DeanCalzada (ASX:CZD) subsidiary PolyNovo will seek marketing approval in the US for NovoSorb, its dressing for hard-to-heal pressure sores.
Alchemia progresses with colorectal cancer trial
04 February, 2013 by Dylan Bushell-EmblingAlchemia (ASX:ACL) has enrolled the 390th patient for its phase III trial of HA-Irinotecan in metastatic colorectal cancer and expects to reach the primary endpoint in early 2014.
AtCor forecasts profit in 2013
31 January, 2013 by Tim DeanMedical device manufacturer AtCor (ASX:ACG) expects to report a profit in this financial year following strong sales of its SphygmoCor diagnostic device.
Pharmaxis stock plummets on negative FDA recommendation
31 January, 2013 by Tim DeanPharmaxis (ASX:PXS) stock has dropped 40% following a negative recommendation from an expert panel that Bronchitol should be approved by the FDA.
The rise of smartphone health and medical apps
31 January, 2013 by Michael Sutton and Megan FraserHealth and medical smartphone apps can help improve the management of acute and chronic conditions and provide more personalised medical treatment.
Major medtech conference moves to Victoria
30 January, 2013 by AusBiotechAusMedtech 2013, Australia’s premier medical technology conference, will be held in Melbourne for the first time on 15-16 May, with the support of the state government of Victoria.
ResMed revenues up thanks to strong sales
30 January, 2013 by Tim DeanResMed (ASX:RMD) has seen revenues increase by 13% for the December quarter year on year with a dividend coming in February.
Mesoblast gets FDA all-clear for arthritis stem cell trial
30 January, 2013 by Dylan Bushell-EmblingThe FDA has approved Mesoblast’s (ASX:MSB) application to conduct a phase II trial of its mesenchymal precursor cells to treat rheumatoid arthritis.
State of the industry to be gauged by its leaders in annual survey
30 January, 2013 by AusBiotechAusBiotech is pleased to once again conduct the annual CEO Industry Position Survey 2013 to get a comprehensive view of the Australian biotechnology sector.
FDA panel to vote on Pharmaxis’s NDA
30 January, 2013 by Dylan Bushell-EmblingAn independent advisory panel will vote today on whether to recommend the US FDA approve Pharmaxis’s (ASX:PSX) NDA for Bronchitol as a cystic fibrosis treatment.
Biotechs up after All Ordinaries surge
30 January, 2013 by Tim DeanLife science stocks have enjoyed a boost alongside the broader share market, with stocks such as CSL (ASX:CSL) hitting historic highs.
Cellmid antibodies reduced kidney damage in mice
24 January, 2013 by Dylan Bushell-EmblingCellmid’s (ASX:CDY) anti-midkine antibodies were able to reduce kidney damage and preserve function in an animal model of diabetic nephropathy.
Uscom protocol slashed sepsis deaths: study
23 January, 2013 by Dylan Bushell-EmblingA Bathurst hospital reduced sepsis-related deaths by 94% by adopting a treatment protocol involving the use of Uscom (ASX:UCM) diagnostics tech, according to a new study.
Allied Healthcare closes $4.6m capital raising
23 January, 2013 by Dylan Bushell-EmblingAllied Healthcare (ASX:AHZ) will put the $4.6m raised in a placement and SPP towards launching its CardioCel heart patch as well as phase I trials of its DNA vaccine against herpes.
Abraxane extends life in advanced pancreatic cancer patients
23 January, 2013 by Tim DeanA phase III trial has shown Celgene’s Abraxane, distributed here by Specialised Therapeutics, has a significant impact on survival in patients with advanced pancreatic cancer.
